Can Mathematical Models Predict the Outcomes of Prostate Cancer Patients Undergoing Intermittent Androgen Deprivation Therapy
暂无分享,去创建一个
Dashiell E. A. Fryer | Yang Kuang | Katrina K. Treloar | Azmy S. Ackleh | Timothy C. Reluga | Yuri S. Semenov | Eduardo Sontag | J. Keener | D. Roose | J. Ottesen | G. Samaey | A. Gumel | Y. Kuang | A. Shilnikov | C. Drapaca | Ucla | A. Cintrón-Arias | Alan Veliz-Cuba | A. Novozhilov | R. Diegelmann | C. Tomasetti | J. Nagy | N. Vaidya | C. Stamoulis | Z. Belkhatir | J. Loros | Mokryun L. Baek | T. Karabiyik | Zahra Aminzare | C. Wolgemuth | J. MacLaurin | Wilten Nicola | J. Schwabedal | A. Packer | S. Mcelwain | R. Malka | Oyita Udiani | M. Garlick | Andrey A Dovzhenok | Johanne Gudmand-Høyer | Isaac Takaidza | J. Juliano | R. A. Everett | Aaron Packer | V. Perminov | Alacia M Voth | R. Waters | Tamra Heberling | R. Everett | Annelies Lejon | Pierre Kornprobst | E. Strawbridge | W. Nicola | O. Faugeras | Rami M. Amro | Xueying Wang | Kristin R Swanson | Santiago Schnell | John Rinzel | Kristin Rae Swanson | Oliver E Jensen | Arthur Tbd | Lander | Alison Tbd | Galvani | Lu J | Norman Mazer | F. Hoffmann | Alan M Hastings | Uc Davis | James J Collins | John G Alford | Edward W. Swim | Ku Leuven | Yongli Cai | Shangbin Cui | Weiming Wang | Thomas W Carr | Adnan Khan | Jing Li | Alexander Neiman | Inria Sophia-Antipolis | Xueying Wang | M. Mehedi | M. Hasan | Philipp Kuegler | Ricam | Angela M Reynolds | Racheal Cooper | Rebecca Segal | Tomas Gedeon | Richard Allen | Cynthia Musante | Maja Skataric | Evgeni Nikolaev | Scott T Bickel | Marc Harper | Alexander Bratus | Swati Patel | Sebastian Schreiber | Luis Gordillo | Christopher Lee | Lihong Zhao | Sue Ann Campbell | Bernard Chang | Li Yang | Arun Mehra | Jay Dunlap | Sookkyung Lim | Christian Hong | Jae Kyoung Kim | Zachary Kilpatrick | Matthew Bennett | Kreimir Josic | Roy Malka | Marcio Duarte | Albasini Mourao | Doree Kreitmann | Samuel A Ramirez | Sridhar Ragavachari | Matthew J. Simpson | Ruth E. Baker | Paulo V Amorim | James Powell | Lisa G Davis | Ryan Lamb | Billie Karens | Bradford Taylor | Georgia Tech | Michael H. Cortez | Joshua Weitz | Michael Li | A. Ackleh | Tomáš Gedeon | Angela M. Reynolds | Rebecca A. Segal
[1] C. Higano. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. , 2003, Urology.
[2] L. Klotz,et al. Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care? , 2012, Current oncology.
[3] Kazuyuki Aihara,et al. Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer. , 2010, Journal of theoretical biology.
[4] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[5] D. Feldman,et al. The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.
[6] Travis Portz,et al. A clinical data validated mathematical model of prostate cancer growth under intermittent androgen suppression therapy , 2012 .
[7] A. Jarkowski,et al. A new era for castrate resistant prostate cancer: A treatment review and update , 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[8] R. Jennrich,et al. Primary intermittent androgen deprivation as initial therapy for men with newly diagnosed prostate cancer. , 2011, Clinical genitourinary cancer.
[9] J. Isaacs,et al. The biology of hormone refractory prostate cancer. Why does it develop? , 1999, The Urologic clinics of North America.
[10] Joseph L. Chin,et al. Intermittent Androgen Suppression for Rising PSA Level After Radiotherapy , 2013 .
[11] M. R. Droop,et al. 25 Years of Algal Growth Kinetics A Personal View , 1983 .
[12] Kazuyuki Aihara,et al. Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression. , 2012, Journal of molecular cell biology.
[13] M. Resnick. Urological cancer: Walking the tightrope of survival and quality of life with ADT , 2013, Nature Reviews Clinical Oncology.
[14] S. Goldenberg,et al. Effects of intermittent androgen suppression on androgen‐dependent tumors. Apoptosis and serum prostate‐specific antigen , 1993, Cancer.
[15] J. Efstathiou,et al. Urological cancer: The benefits of intermittent androgen-deprivation therapy , 2012, Nature Reviews Clinical Oncology.
[16] A. Jemal,et al. Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.
[17] F. Labrie. Blockade of testicular and adrenal androgens in prostate cancer treatment , 2011, Nature Reviews Urology.
[18] R W Veltri,et al. Implication of cell kinetic changes during the progression of human prostatic cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] Thomas L. Jackson,et al. A mathematical model of prostate tumor growth and androgen-independent relapse , 2003 .
[20] Donna L Berry,et al. Intermittent versus continuous androgen deprivation in prostate cancer. , 2013, The New England journal of medicine.
[21] W. Gerald,et al. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. , 2004, Endocrine-related cancer.
[22] Jeffrey C. Lagarias,et al. Convergence Properties of the Nelder-Mead Simplex Method in Low Dimensions , 1998, SIAM J. Optim..
[23] W. Dahut,et al. Androgen deprivation therapy for prostate cancer. , 2005, JAMA.
[24] P. Nelson. Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Trachette L. Jackson,et al. A mathematical investigation of the multiple pathways to recurrent prostate cancer: comparison with experimental data. , 2004, Neoplasia.
[26] Gouhei Tanaka,et al. A Mathematical Model of Intermittent Androgen Suppression for Prostate Cancer , 2008, J. Nonlinear Sci..
[27] M. Gleave,et al. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer. , 2009, Urologic oncology.
[28] Mette S Olufsen,et al. Rarefaction and blood pressure in systemic and pulmonary arteries , 2012, Journal of Fluid Mechanics.